In News

Follow this topic

Bookmark

Record learning outcomes

Over half of the active products in the global industry research pipeline are personalised medicines €“ but the UK healthcare system is at risk of failing to adapt to this new challenge, a new report from the ABPI has revealed.

The discussion paper, 'Securing a Future for Innovative Medicines', highlights further challenges including rising drug development costs and difficulty with patient recruitment for clinical trials. The UK needs to improve trial performance by enabling faster patient enrolment, encouraging the use of electronic health records and streamlining the research governance process, the ABPI says.